Another win for Vascepa: Pricing watchdog ICER calls Amarin's fish-oil pill cost-effective

24th July 2019 Uncategorised 0

Amarin is betting big on its fish-oil derivative Vascepa with a $400 million cash raise to boost its marketing ahead of an expected label expansion. A nod of approval from a U.S. cost watchdog could kick those hopes into overdrive.

More: Another win for Vascepa: Pricing watchdog ICER calls Amarin's fish-oil pill cost-effective
Source: fierce